Serum levels of matrix metalloproteinase-1 in Brazilian patients with benign prostatic hyperplasia or prostate cancer
Uloženo v:
| Hlavní autor: | |
|---|---|
| Datum vydání: | 2020 |
| Další autoři: | , , , , , , |
| Médium: | Article |
| Jazyk: | eng |
| Zdroj: | Repositório Institucional da UnB |
| Download full: | http://repositorio2.unb.br/jspui/handle/10482/47427 https://doi.org/10.1155/2020/6012102 https://orcid.org/0000-0003-1511-0387 https://orcid.org/0000-0003-1775-7176 |
Shrnutí: | Metalloproteinases (MMPs) are involved in metastatic tumor processes, with changes in circulating levels detected in several cancer types. Here, we compare serum concentrations of metalloproteinase-1 (MMP-1) across individuals clinically diagnosed with prostate cancer (PCa) or benign prostatic hyperplasia (BPH), correcting results for the rs495366 single nucleotide polymorphism (SNP) that predisposes to differential MMP-1 levels. 196 men aged ≥50 years were followed at a university hospital urology outpatient clinic, with clinical, anthropometric, and rectal examinations performed by one urologist. Blood samples obtained prior to any clinical intervention provided baseline MMP-1 and total/free PSA levels as well as metabolic, hormonal, and inflammatory markers. +e SNP was genotyped by real-time PCR. Participants with medical and/or laboratory profile compatible with malignancy composed the PCa group when confirmed by the Gleason scale. As expected, A-allele homozygotes showed reduced levels of MMP-1. Genotype-adjusted analyses revealed the mean MMP-1 level as 2-fold higher in PCa carriers compared to BPH patients. No other differences were found according to the prostatic condition or genotypic distribution, except for the expected raise in total and free PSA levels in PCa. In conclusion, increased serum levels of MMP-1 were observed in this context of prostatic malignancy compared to a benign phenotype, regardless of a genetic influence. |
Podobné jednotky: Serum levels of matrix metalloproteinase-1 in Brazilian patients with benign prostatic hyperplasia or prostate cancer
- Prognostic value of morphologic and clinical Pparameters in pT2 - pT3 prostate cancer
- ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia
- Análise de mediadores inflamatórios sistêmicos em pacientes portadores de câncer de próstata e de hiperplasia prostática benigna
- PSMA-bearing extracellular vesicles secreted from prostate cancer convert the microenvironment to a tumor-supporting, pro-angiogenic state
- Fatigue and muscle function in prostate cancer survivors receiving different treatment regimens
- Síntese e avaliação farmacológica de novos antagonistas alfa-adrenérgicos